Compare MRNA & HAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRNA | HAL |
|---|---|---|
| Founded | 2010 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 27.9B |
| IPO Year | 2018 | 2006 |
| Metric | MRNA | HAL |
|---|---|---|
| Price | $145.11 | $35.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 18 |
| Target Price | $34.27 | ★ $38.61 |
| AVG Volume (30 Days) | ★ 16.7M | 10.2M |
| Earning Date | 05-01-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.63% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 1.19 |
| Revenue | ★ $19,263,000,000.00 | $17,973,000,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $15.43 | $4.19 |
| P/E Ratio | ★ N/A | $29.99 |
| Revenue Growth | 4.29 | ★ 22.47 |
| 52 Week Low | $22.28 | $21.40 |
| 52 Week High | $176.66 | $43.59 |
| Indicator | MRNA | HAL |
|---|---|---|
| Relative Strength Index (RSI) | 72.44 | 59.23 |
| Support Level | $41.01 | $33.08 |
| Resistance Level | N/A | $35.88 |
| Average True Range (ATR) | 10.94 | 0.83 |
| MACD | 10.45 | 0.44 |
| Stochastic Oscillator | 75.89 | 83.73 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Halliburton is North America's largest oilfield-services company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. Halliburton's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been honed over a century of operations.